-
公开(公告)号：US20050261310A1
公开(公告)日：2005-11-24
申请号：US11104041
申请日：2005-04-12
申请人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian Metcalf
发明人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian Metcalf
IPC分类号： A61K31/496 , A61K45/06 , C07D401/06 , C07D401/14 , C07D417/14 , C07D471/04 , C07D43/04
CPC分类号： C07D401/14 , A61K31/496 , A61K31/502 , A61K31/506 , A61K45/06 , C07D401/06 , C07D417/14 , C07D471/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
摘要翻译： 本发明涉及式I化合物：其中可变取代基在本文中定义，其调节趋化因子受体如CCR5的活性或与其结合。 在一些实施方案中，本发明的化合物对CCR5是选择性的。 该化合物可用于例如治疗与趋化因子受体表达或活性相关的疾病，例如炎性疾病，免疫疾病和病毒感染。
-
公开(公告)号：US20120295912A1
公开(公告)日：2012-11-22
申请号：US13564434
申请日：2012-08-01
申请人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian W. Metcalf
发明人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian W. Metcalf
IPC分类号： A61K31/506 , A61K31/496 , A61P29/00 , C12N5/071 , A61P31/12 , A61P31/18 , A61P37/06 , A61K31/502 , A61P37/00
CPC分类号： C07D401/14 , A61K31/496 , A61K31/502 , A61K31/506 , A61K45/06 , C07D401/06 , C07D417/14 , C07D471/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
摘要翻译： 本发明涉及式I化合物：其中可变取代基在本文中定义，其调节趋化因子受体如CCR5的活性或与其结合。 在一些实施方案中，本发明的化合物对CCR5是选择性的。 该化合物可用于例如治疗与趋化因子受体表达或活性相关的疾病，例如炎性疾病，免疫疾病和病毒感染。
-
公开(公告)号：US07678798B2
公开(公告)日：2010-03-16
申请号：US11104041
申请日：2005-04-12
申请人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian W. Metcalf
发明人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian W. Metcalf
IPC分类号： A61K31/497 , C07D247/02 , A61K31/496 , A61P29/00 , C07D237/28 , C07D487/00 , C07D401/04 , C07D403/04 , C07D405/04 , C07D409/04 , C07D411/04 , C07D413/04 , C07D417/04 , C07D419/04 , C07D241/04 , C07D277/22 , C07D307/78 , C07D303/08 , C07C49/297 , C07C33/46
CPC分类号： C07D401/14 , A61K31/496 , A61K31/502 , A61K31/506 , A61K45/06 , C07D401/06 , C07D417/14 , C07D471/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
摘要翻译： 本发明涉及式I化合物：其中可变取代基在本文中定义，其调节趋化因子受体如CCR5的活性或与其结合。 在一些实施方案中，本发明的化合物对CCR5是选择性的。 该化合物可用于例如治疗与趋化因子受体表达或活性相关的疾病，例如炎性疾病，免疫疾病和病毒感染。
-
公开(公告)号：US08268826B2
公开(公告)日：2012-09-18
申请号：US12422517
申请日：2009-04-13
申请人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian W. Metcalf
发明人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian W. Metcalf
IPC分类号： A61P29/00 , A61P31/12 , A61P37/00 , C07D237/28 , C07D401/14 , A61K31/502 , C07D403/14 , A61K31/501
CPC分类号： C07D401/14 , A61K31/496 , A61K31/502 , A61K31/506 , A61K45/06 , C07D401/06 , C07D417/14 , C07D471/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
摘要翻译： 本发明涉及式I化合物：其中可变取代基在本文中定义，其调节趋化因子受体如CCR5的活性或与其结合。 在一些实施方案中，本发明的化合物对CCR5是选择性的。 该化合物可用于例如治疗与趋化因子受体表达或活性相关的疾病，例如炎性疾病，免疫疾病和病毒感染。
-
5.发明申请公开(公告)号：US20100190981A1
公开(公告)日：2010-07-29
申请号：US12687623
申请日：2010-01-14
申请人： Jiacheng Zhou , Pingli Liu , Qiyan Lin , Brian W. Metcalf , David Meloni , Yongchun Pan , Michael Xia , Mei Li , Tai-Yuen Yue , James D. Rodgers , Haisheng Wang
发明人： Jiacheng Zhou , Pingli Liu , Qiyan Lin , Brian W. Metcalf , David Meloni , Yongchun Pan , Michael Xia , Mei Li , Tai-Yuen Yue , James D. Rodgers , Haisheng Wang
IPC分类号： C07D487/04 , C07D231/16 , C07F5/02
CPC分类号： C07D487/04 , C07F5/025 , C07F7/083 , C07F7/10 , C07F7/1892 , Y02P20/55
摘要： The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
摘要翻译： 本发明涉及制备式III的手性取代吡唑并吡咯并[2,3-d]嘧啶的方法和相关的合成中间体化合物。 手性取代的吡唑基吡咯并[2,3-d]嘧啶可用作Janus Kinase家族蛋白酪氨酸激酶（JAKs）的抑制剂，用于治疗炎性疾病，骨髓增生性疾病和其他疾病。
-
6.发明授权公开(公告)号：US09000161B2
公开(公告)日：2015-04-07
申请号：US13761742
申请日：2013-02-07
申请人： Jiacheng Zhou , Pingli Liu , Qiyan Lin , David Meloni , Yongchun Pan , Michael Xia , Mei Li , Tai-Yuen Yue , Brian W. Metcalf
发明人： Jiacheng Zhou , Pingli Liu , Qiyan Lin , David Meloni , Yongchun Pan , Michael Xia , Mei Li , Tai-Yuen Yue , Brian W. Metcalf
IPC分类号： C07D487/00 , C07D487/04 , C07F7/18 , C07F7/10
CPC分类号： C07D487/04 , C07F5/025 , C07F7/083 , C07F7/10 , C07F7/1892 , Y02P20/55
摘要： The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
摘要翻译： 本发明涉及制备式III的手性取代吡唑并吡咯并[2,3-d]嘧啶的方法和相关的合成中间体化合物。 手性取代的吡唑基吡咯并[2,3-d]嘧啶可用作Janus Kinase家族蛋白酪氨酸激酶（JAKs）的抑制剂，用于治疗炎性疾病，骨髓增生性疾病和其他疾病。
-
公开(公告)号：US20090233903A1
公开(公告)日：2009-09-17
申请号：US12401348
申请日：2009-03-10
申请人： James D. Rodgers , Stacey Shepard , Yun-Long Li , Jiacheng Zhou , Pingli Liu , David Meloni , Michael Xia
发明人： James D. Rodgers , Stacey Shepard , Yun-Long Li , Jiacheng Zhou , Pingli Liu , David Meloni , Michael Xia
IPC分类号： A61K31/519 , C07D487/04 , A61P35/00
CPC分类号： C07D487/04 , B60Q3/76 , B60Q3/80 , Y10S362/80 , Y10S362/802
摘要： The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
摘要翻译： 本发明涉及氮杂环丁烷和环丁烷衍生物，以及它们的组合物，使用方法和制备方法，其是可用于治疗JAK相关疾病（包括例如炎性和自身免疫性疾病）的JAK抑制剂，以及 作为癌症。
-
公开(公告)号：US08993582B2
公开(公告)日：2015-03-31
申请号：US13761830
申请日：2013-02-07
申请人： Jiacheng Zhou , David Meloni , Pingli Liu , Brian W. Metcalf , Tai-Yuen Yue
发明人： Jiacheng Zhou , David Meloni , Pingli Liu , Brian W. Metcalf , Tai-Yuen Yue
IPC分类号： A01N43/90 , A61K31/519 , C07D487/00 , C07D487/04 , C07F7/18 , C07F7/10
CPC分类号： C07D487/04 , C07F5/025 , C07F7/083 , C07F7/10 , C07F7/1892 , Y02P20/55
摘要： The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
-
公开(公告)号：US08410265B2
公开(公告)日：2013-04-02
申请号：US12687623
申请日：2010-01-14
申请人： Jiacheng Zhou , Pingli Liu , Qiyan Lin , Brian W. Metcalf , David Meloni , Yongchun Pan , Michael Xia , Mei Li , Tai-Yuen Yue , James D. Rodgers , Haisheng Wang
发明人： Jiacheng Zhou , Pingli Liu , Qiyan Lin , Brian W. Metcalf , David Meloni , Yongchun Pan , Michael Xia , Mei Li , Tai-Yuen Yue , James D. Rodgers , Haisheng Wang
IPC分类号： C07D487/00
CPC分类号： C07D487/04 , C07F5/025 , C07F7/083 , C07F7/10 , C07F7/1892 , Y02P20/55
摘要： The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.048 秒)
